Innovative Chemotherapies for Stage III Colon Cancer: A Cost-Effectiveness Study

Hepato-Gastroenterology

Volumn 50, Issue 54, 2003, Pages 1903-1909

  Koperna, T ^a   Semmler, D ^a  

^a Hospital Mistelbach   (Austria)

Author keywords

Chemotherapy; Colon cancer; Cost effectiveness; Irinotecan; Oxaliplatin

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ACCURACY; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; COLON CANCER; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; HUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; DRUG COSTS; FEMALE; FLUOROURACIL; HOSPITAL COSTS; HUMANS; LENGTH OF STAY; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROSPECTIVE STUDIES; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL RATE;

EID: 0345392816     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Laurie JA, Moertel CG, Fleming TR, Wieand HS, Leigh JE, Rubin J, et al: Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and Fluorouracil. J Clin Oncol 1989; 7:1447-1456.
2. Moertel CG, Fleming TR, MacDonald JS, Haller DG, Laurie JA, Goodman PJ, et al: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322:352-358.
3. NIH Consensus Conference: Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990; 264:1444-1450.
4. Brown ML, Nayfield SG, Shibley LM: Adjuvant therapy for stage III colon cancer: economics returns to research and cost-effectiveness of treatment. J Natl Cancer Inst 1994; 86:424-430.
5. Michel P, Merle V, Chiron A, Ducrotte P, Paillot B, Hecketsweiler P, Czernichow P, Colin R: Postoperative management of stage II/III colon cancer: a decision analysis. Gastroenterology 1999; 117:784-793.
6. Dube S, Heyen F, Jenicek M: Adjuvant chemotherapy in colorectal carcinoma. Results of a meta-analysis. Dis Colon Rectum 1997; 40:35-41.
7. Buyse M, Piedbois P: Should Dukes B patients receive adjuvant therapy? A statistical perspective. Semin Oncol 2001; 28:20-24.
8. Diaz-Canton EA, Pazdur R: Adjuvant medical therapy for colorectal cancer. Surg Clin North Am 1997; 77:211-228.
9. International Multicentre Pooled Analysis of B2 Colon Cancer Trials Investigators: Efficacy of adjuvant Fluorouracil and Folinic acid in B2 Colon Cancer. J Clin Oncol 1999; 17:1356-1363.
10. International Multicenter Pooled Analysis of Colon Cancer Trials Investigators: Efficacy of adjuvant Fluorouracil and Leucovorin in stage B2 and C Colon Cancer. Semin Oncol 2001; 28:14-19.
11. Moertel CG, Fleming TR, MacDonald JS, Haller DG, Laurie JA, Tangen CM, et al: Intergroup study of Fluorouracil plus Levamisole as adjuvant therapy for stage II/Dukes B2 colon cancer. J Clin Oncol 1995; 13:2936-2943.
12. Mamounas E, Wieand S, Wohnark N, Bear HD, Atkins JN, Song K, et al: Comparative efficacy of adjuvant chemotherapy in patients with Dukes B versus Dukes C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, C-04). J Clin Oncol 1999; 17:1349-1355.
13. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al: Leucovorin and Fluorouracil with or without Oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-2947.
14. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, et al: Phase III multicenter randomized trial of Oxaliplatin added to chronomodulated Fluorouracil-Leukovorin as first line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18:136-147.
15. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al: Irinotecan combined with Fluorouracil compared with Fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355:1041-1047.
16. Rougier P, van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, et al: Randomised trial of Irinotecan versus Fluorouracil by continuous infusion after Fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352:1407-1412.
17. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al: Irinotecan plus Fluorouracil and Leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343:905-914.
18. Sargent DJ, Niedzwiecki D, O/Connell MJ, Schilsky RL: Recommendation for caution with Irinotecan, Fluorouracil, and Leucovorin for colorectal cancer. N Engl J Med 2001; 345:144-145. (Letter)
19. Francini G, Petrioli R, Lorenzini L, Mancini S, Armenio S, Tanzini G, et al: Folinic acid and 5-Fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology 1994; 106:899-906.
20. International Multicentre Pooled Analysis of Colon Cancer Trials Investigators: Efficacy of adjuvant Fluorouracil and Folinic acid in colon cancer. Lancet 1995; 345:939-944.
21. Moertel CG, Fleming TR, MacDonald JS, Haller DG, Laurie JA, Tangen CM, et al: Fluorouracil plus Levamisole as effective adjuvan therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995; 122:321-326.
22. O'Connell MJ, Maillard JA, Kahn MJ, MacDonald JS, Haller DG, Mayer RJ, Wieand HS: Controlled trial of Fluorouracil and low-dose Leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997; 15:246-250.
23. Wolmark N, Fisher B, Rockette H, Redmond C, Wickerham DL, Fisher ER, et al: Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst 1988; 80:30-36.
24. Zaniboni A, Labianca R, Marsoni S, Torri V, Mosconi P, Grilli R, et al: GIVIO-SITAC 01. A randomized trial of adjuvant 5-Fluorouracil and Folinic acid administered to patients with colon carcinoma - long term results and evaluation of the indicators of health-related quality of life. Cancer 1998; 82:2135-2144.
25. O'Connell MJ: A phase III trial of 5-Fluorouracil and Leucovorin in the treatment of advanced colorectal cancer. Cancer 1989; 63:1026-1030.
26. Poon MA, O/Connell MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, et al: Biochemical modulation of Fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7:1407-1418.
27. de Gramont A, Vignoud J, Tournigand C, Louvet C, AndreT, Varette C, et al: Oxaliplatin with high-dose Leucovorin and 5-Fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997; 33:214-219.
28. Andre T, Bensmaine MA, Louvet C, Francois E, Lucas V, Desseigne F, et al: Multicenter phase II study of bimonthly high-dose Leucovorin, Fluorouracil infusion, and Oxaliplatin for metastatic colorectal cancer resistant to the same Leucovorin and Fluorouracil regimen. J Clin Oncol 1999; 17:3560-3568.
29. Cairns JA, van der Pol MM: The estimation of marginal time preference in a UK-wide sample (TEMPUS) project. Health Technol Assessment 2000; 4(1).
30. de Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, et al: Randomized trial comparing monthly low-dose Leucovorin and Fluorouracil bolus with bimonthly high-dose Leucovorin and Fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997; 15:808-815.
31. Heriot AG, Kumar D: Adjuvant therapy for resectable rectal and colonic cancer. Br J Surg 1998; 85:300-309.
32. Wolmark N, Rockette H, Fisher B, Wickerham DL, Redmond C, Fisher ER, et al: The benefit of Leucovorin-modulated Fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from NSABP protocol C-03. J Clin Oncol 1993; 11:1879-1887.
33. Gastrointestinal Tumor Study Group: Adjuvant therapy of colon cancer: results of a prospectively randomised trial. N Engl J Med 1984; 310:737-743.
34. Giles GR, Lawton JO, Malhotra A, Hall R, Matheson TS, Craven JL, MacAdam WAF, Bird GG: Chemotherapy after palliative resection of colorectal cancer. Br J Surg 1984; 71:283-286.
35. Allen-Mersh TG, Earlam S, Fordy C, Abrams K, Houghton J: Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet 1994; 344:1255-1260.
36. Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D: Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993; 306:752-755.
37. Vanhoefer U, Harstrick A, Achterrath W, Cao S, Seeber S, Rustum YM: Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol 2001; 19:1501-1518.
38. Tournigand C, Achille E, Lledo G, Flesh M, Risse ML, Ganem G, et al: FOLFIRI followed by FOLFOX or FOLFOX followed by FOLFIRI in metastatic colorectal cancer. Preliminary data of a randomised phase III study of the GERCOR. Ann Oncol 2000; 11:43. (Abstract)
39. Levi F, Zidani R, Misset JL: Randomised multicentre trial of chronotherapy with Oxaliplatin, Fluorouracil, and Folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet 1997; 350:681-686.
40. Adam R, Avisar E, Ariche A, Giachetti S, Azoulay D, Castaing D, et al: Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 2001; 8:347-353.
41. Bismuth H, Adam R, Levi F, Farabos C, Waechter F, Castaing D, et al: Resection of nonresectable liver metas-tases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224:509-522.
42. Giachetti S, Itzhaki M, Gruia G, Adam R, Zidani R, Kunstlinger F, et al: Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-Fluorouracil, Leucovorin, Oxaliplatin and surgery. Ann Oncol 1999; 10:663-669.
43. Ducreux M, Ychou M, Seitz JF, Bonnay M, Bexon A, Armand JP, et al: Irinotecan combined with bolus Fluorouracil, continuous infusion Fluorouracil, and high-dose Leucovorin every two weeks: a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. J Clin Oncol 1999; 17:2901-2908.
44. Kemeny N, Gonen M, Sullivan D, Schwartz L, Benedetti F, Saltz L, et al: Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. J Clin Oncol 2001; 19:2687-2695.
45. Jarnagin W, Kemeny N, Sullivan D, Blumgart L, Paty P, DeMatteo R, et al: A phase I-II study of hepatic arterial infusion with Floxuridine and Dexamethason in combination with systemic Irinotecan after resection of hepatic metastases from colorectal cancer. Proc ASCO 2001; 20:508. (Abstract)
46. Abramson RG, Rosen MP, Perry LJ, Brophy DP, Raeburn SL, Stuart KE: Cost-effectiveness of hepatic arterial chemoembolization for colorectal liver metastases refractory to systemic chemotherapy. Radiology 2000; 216:485-491.
47. Durand-Zaleski I, Earlam S, Fordy C, Davies M, Allen-Mersh TG: Cost-effectiveness of systemic and regional chemotherapy for the treatment of patients with unresectable colorectal liver metastases. Cancer 1998; 83:882-888.
48. Tominaga T, Sakabe T, Koyama Y, Hamano K, Yasutomi M, Takahashi T, et al: Prognostic factors for patients with colon or rectal carcinoma treated with resection only. Cancer 1996; 78:403-408.
49. Cunningham D, Falk S, Jackson DL: Irinotecan in first line treatment of metastatic colorectal cancer: improved survival and cost-effective compared with infusional 5-FU. Eur J Cancer 2000; 36:S18. (Abstract)
50. Schmitt C, Levy-Piedbois C, Frappe M, Durand-Zaleski I: Cost-effectiveness analysis of Irinotecan as first-line therapy in advanced colorectal cancer. Eur J Cancer 2000; 36:S24. (Abstract)
51. Trippoli S, Vaiani M, Cattel F, Messori A: Cost-effectiveness of irinotecan in advanced colorectal cancer. Ann Oncol 2000; 11:899-900. (Letter)
52. Vaiani M, Trippoli S, Messori A: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2001; 344:305-306. (Letter)
53. Trippoli S, Vaiani M, Messori A, Tendi E: Survival gain in cost-effectiveness studies. J Clin Oncol 2000; 18:3318. (Letter)
54. Koperna T, Kisser M, Schulz F: Hepatic resection in the elderly. World J Surg 1998; 22:406-412.
55. QUASAR Collaborative Group: Comparison of Fluorouracil with additional Levamisole, higher-dose Folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. Lancet 2000; 355:1588-1596.
56. Wolmark N, Rockette H, Mamounas E, Jones J, Wieand S, Wickerham DL, et al: Clinical trial to assess the relative efficacy of Fluorouracil and Leucovorin, Fluorouracil and Levamisole, and Fluorouracil, Leucovorin, and Levamisole n patients with Dukes B and C carcinoma of the colon: results from NSABP C-04. J Clin Oncol 1999; 17:3553-3559.
57. Andre T, Colin P, Louvet C, Gamelin E, Bouche O, Achille E, et al: Randomized adjuvant study comparing two schemes of 5-Fluorouracil and Leucovorin in stage B2 and C colon adenocarcinoma: study design and preliminary safety results. Semin Oncol 2001; 28:35-40.